

**TICKER: 4167**



**Savior Lifetec Corporation**  
**March 2020**

**SLC**

# DISCLAIMER

---

This presentation has been provided by Savior Lifetec Corporation (SLC) for informational purposes only. It is not an offer to buy or sell or a solicitation of an offer to buy or sell any security issued by SLC or other parties.

This presentation may contain forward-looking statements which reflect SLC management's views, estimates, and currently available information. These statements are SLC management's opinion and SLC does not provide warranty for the accuracy, reliability, and completeness of the information. Investors should not place undue reliance on the statements, as there are significant risks that could cause actual results or future developments to differ materially from those expressed or implied by forward looking statements. Potential risks include economic conditions, foreign exchange fluctuations, competitive product and pricing pressures, and regulatory developments.

SLC has no obligation to update any forward-looking statement or figures, whether as a result of new information, future events, or otherwise.

# Agenda

---





# About SLC


Established : 2004/1/30

OTC : 2015/9/8

Product and Service Scope :


- Penem Injectables
- Non-Penem Injectables
- CDMO service

Capital : NT2.5 billion



# Major Milestones

- = API
- = Injectable
- = CDMO



# SLC's Status in Taiwan Generic Drug Industry

---The comparison of Injectable ANDAs Owned by Taiwan Companies

Active Ingredient	ANDA Applicant	ANDA Year	Marketer	Launch Year	Own API	Own FDF	ANDAs Approved*	MKT (\$,mn)	MKT Price (\$/Unit)
Ertapenem Sodium	Savior	2019	Apotex	2019	V	V	3	377	\$ 104
Meropenem	Savior	2016	Sandoz	2016	V	V	8	261	\$ 19
Linezolid	Nang Kuang	2016	Sun	2017		V	7	86	\$ 0.18
Fondaparinux Sodium	Scinopharm	2018	Zydus	N/A	V		4	77	\$ 64
Desmopressin Acetate	UBI Pharma	2020	UBI	N/A		V	5	53	\$ 61
Terbutaline Sulfate	United Biomedical	2013	Athenex	2017		V	6	6	\$ 9

\* Eliminates discontinued and repeated ANDAs


- Taiwan's Only Vertically Integrated Injectable Supplier
- Taiwan's 2nd Injectable ANDA By Approval Year
- Ertapenem are Taiwan's 1st Largest Generic Injectable Drugs by Market
- Ertapenem is Taiwan's the Highest Unit Price Generic Injectable Drug
- Ertapenem is Taiwan's the Highest Competition Generic Injectable Drug
- Meropenem are Taiwan's 2nd Largest Generic Injectable Drugs by Market

# SLC will be the leader in Taiwan's pharmaceutical in 2020

				(NT\$m)
	2018	2017	2016	2015
Taiwan injectable exported US	3,292	3,489	3,156	2,422

Source: 2015-2018 Biotechnology Industry in Taiwan

**SLC exports US revenue to NT \$ 700 million in 2019.**



**About 20% of Taiwan injectable exported US.**






# COVID-19 drive global hospital demand

*The medications identified are priority [pharmaceuticals] recommended in guidelines applicable for the management of Coronavirus Respiratory Infections by Novartis:*

Antibiotics	Hospital Care Products	Antivirals
Amoxicillin	Dobutamine	Lopinavir/Ritonavir
AmoxiClav	Ranitidine	Ribavirin
Piperacillin/Tazobactam	Omeprazole	Oseltamivir
Ceftriaxone	Pantoprazole	Atazanavir
Clarithromycin	Heparin	Efavirenz
Levofloxacin	Enoxaparin	Ritonavir
Meropenem		Dolutegravir
Vancomycin		
Gentamicin		
Tigecycline		

# COVID-19 disrupting the global supply






# 2019 Income Statement

(\$mn)	3Q19	4Q19	2019
Net Sales	341	375	1319
COGS	248	239	968
Gross Profit	93	136	351
Gross Margin	27%	36%	27%
Operating Expense	83	70	296
Operating Income	10	66	55
Operating Margin	3%	18%	4%
Non-Op Income (Expense)	(8)	(25)	(60)
Net Income	2	41	(5)
Net Margin	0%	11%	(0%)
EPS	0.01	0.15	(0.02)
-----			
Cash & Cash Equivalents	623	559	559

# Market share in 2019

**America market share will continue to grow in 2020**






# Meropenem Global Market Continues to Grow

## 2019 Global Market US \$1,538mn

(Metric Tons)

### Global Quantity





# The US Market Trend

---

**According to a report by ASHP on 2020/03/04 , there is a supply shortage of Meropenem Injection in the US market.**

3/4/2020

## Meropenem Injection

---


### Products Affected - Description

- Meropenem injection, AuroMedics, 1 gram, vial, 10 count, NDC 55150-0208-30
- Meropenem injection, AuroMedics, 500 mg, vial, 10 count, NDC 55150-0207-20
- Meropenem injection, Pfizer, 1 gram, vial, 25 count, NDC 00409-3506-01 - discontinued
- Meropenem injection, Pfizer, 500 mg, vial, 25 count, NDC 00409-3505-01 - discontinued
- Meropenem injection, Sandoz, 1 gram, vial, 10 count, NDC 00781-3098-95
- Meropenem injection, Sandoz, 1 gram, vial, 25 count, NDC 00781-3098-96
- Meropenem injection, Sandoz, 500 mg, vial, 10 count, NDC 00781-3000-95
- Meropenem injection, Sandoz, 500 mg, vial, 25 count, NDC 00781-3000-96

**There are 3 / 6 meropenem injection products shortage,brings opportunities to increase U.S. market share.**

# Ertapenem Global Market

2019 Global Market US \$460mn



Source: IMS

---

# Q&A